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Editorial
Oral Anti-Platelet Therapy: The Good and the Bad
CHU-PAK LAU,1 WAI-HONG CHEN,1 KAM-CHUEN LAI2
From Divisions of Cardiology1 and Gastroenterology2, University Department of Medicine, Queen Mary Hospital,
The University of Hong Kong, Hong Kong

In 1998, 16.6 and 10.1% of patients died of heart
and cerebrovascular diseases respectively. The main
disease process is underlying atherosclerosis. In the
coronary arteries, rupture or fissure of a vulnerable
plaque is followed by thrombosis, with acute narrowing
of the coronary artery that results in acute coronary
syndrome (ACS).1 The key to thrombotic occlusion is
the platelets, which can be activated by multiple
mechanisms including thromboxane A2, ADP, thrombin,
collagen, and others. Once activated, platelet thrombus
will be formed by fibrinogen binding to IIb/IIIa
receptors.
If platelet activation is the critical step from
atherosclerosis to thrombosis, then anti-platelet agents
will have beneficial effects in patients with established
atherosclerosis. The evidence is compelling and extends
to patients with high risk of atherosclerosis such as those
with diabetes or on haemodialysis. On the other hand,
evidence for primary prevention remains more
controversial, and has to be balanced against the "bad"
side effects of treatment. This editorial addresses the
controversy in the use of oral anti-platelet therapy. The
role of IIb IIIa inhibitors which are only effective with
intravenous administration in ACS has been reviewed.2
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recently published a meta-analysis of randomized trials
of anti-platelet therapy in patients with high risk of
occlusive vascular disease.3 They reviewed 287 trials
before September 1997, involving a total of 212,000
patients. With the endpoints of "serious vascular events"
that include non-fatal myocardial infarction, non-fatal
stroke and vascular death, this meta-analysis shows that
anti-platelet therapy reduces a serious vascular event in
3.6 patients per 1000 treated for 2 years. This risk
reduction is about 1/3 for non-fatal myocardial
infarction, 1/4 for non-fatal stroke and 1/6 for vascular
death (Table). The benefits exceed the bleeding risks in
all categories of high risk patients.
This analysis also sheds light on the following
practical aspects of anti-platelet prescriptions. Aspirin
is most widely used, and a dose of 75-325 mg is at least
as effective as higher daily doses. Indeed, a recent study
on the use of high (700 mg/day) versus low dose (≤325
mg/day) of aspirin in patients undergoing carotid
endartherectomy suggested that the higher dose was
associated with more vascular events than the lower
dose.4 While doses <75 mg/day may be less ulcerogenic
by preserving endothelial prostacycline, this low dose
has only been examined in a few studies.
Are newer thienopyridines better than aspirin? In
patients who presented with ACS treated with aspirin
alone, recurrent myocardial infaction or death still
occurred in about 10% at 1 year. 5 Thus the use of
thienopyridines either alone or in combination with
aspirin for maximum anti platelet effects is attractive.
In the randomized trial of clopidogrel versus aspirin in
patients with ACS (CAPRIE trial)6, clopidogrel reduced
major vascular events by 8.7% [95% CI 0.3-16.5%] over
aspirin. The benefit was marginal and occurred mainly
in patients with an initial diagnosis of peripheral vascular
disease. However, the combined treatment of aspirin and
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Table. Summary of major vascular risk reduction with anti-platelet therapy in various high risk vascular
diseases from the Antithrombotic Trialists' Collaboration study3
Disease status
Old Myocardial Infarction
Acute Myocardial Infarction
Unstable Angina
Coronary Artery Bypass Grafting
Percutaneous Coronary Intervention
Heart Failure
Old Stroke / Transient Ischaemic Attack
Acute Stroke
Carotid Disease
Grafting for Peripheral Vascular Disease
Peripheral Angioplasty
Haemodialysis
Diabetes
Atrial Fibrillation

Trials (n)
12
15
12
25
9
2
21
7
6
12
4
14
9
4

clopidogrel is now standard for patients undergoing
coronary stenting. In patients with ACS, the combination
is shown to be superior to aspirin alone in reducing major
vascular events by about 20%.7 Interestingly, the benefits
occurred early within hours of initiating treatment, were
maintained for up to 12 months, and were present for
patients who subsequently underwent coronary
angioplasty.8 There was a small risk of extracranial
bleeding, most related to vascular access site for
angioplasty. An excellent cost-benefit analysis of
clopidogrel versus aspirin use has recently been
published in the Journal.9
An important complication of aspirin is
gastrointestinal bleeding (GIB). While aspirin may cause
three times lower bleeding complications than other nonsteroidal anti-inflammatory agents,10 acute endoscopic
study suggested that >60% of patients had gastric
abnormalities. 11 Chronic long term bleeding is less
common, and clinically evident GI bleeding occurred
in 3% of elderly patients receiving 100 mg/day of aspirin
for 12 months.12 High risk factors for aspirin related
bleeding include advanced age, previous ulcer,
concomitant use of non-steroidal anti-inflammatory
drugs or wafarin. Infection with Helicobacter pylori may
increase the risk for GIB.13 Several pieces of information
become available to guide our management and
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Patients / controls
9984 / 10022
9658 / 9644
2497 / 2534
3105 / 3126
1592 / 1620
66 / 68
11493 / 11527
20418 / 20403
339 / 337
1249 / 1248
472 / 474
1333 / 1371
2568 / 2558
1390 /1380

Risk reduction
- 25%
- 30%
- 46%
- 4%
- 53%
- 41%
- 22%
- 11%
- 19%
- 22%
- 29%
- 41%
- 7%
- 34%

prevention of aspirin related GIB (Figure). Obviously,
modifiable factors should be corrected or avoided.
Proton pump inhibitor in addition to aspirin is effective
to prevent a re-bleed.14 Another option is to eradicate
H. pylori, and to continue aspirin afterwards.15 This is
as effective as proton pump inhibitor to prevent rebleeding over a 6-month period. Theoretically,
clopidogrel may be used as it is unlikely to be
ulcerogenic, but as yet there is no trial in this setting.
Do we prescribe ulcer prophylactic treatment or
screen all cases for H. pylori (with a view to eradication)
before we initiate aspirin treatment? Due to the general
safety of aspirin and low incidence of GIB, the latter
option is probably not a cost effective measure. While
enteric coated aspirin may reduce dyspepsia, it does not
prevent GIB. For low-risk subjects, low dose aspirin
can be started without prophylaxis. In high risk subjects,
co-therapy with a proton pump inhibitor may be a useful
strategy. Clopidogrel is associated with a lower
incidence of primary GIB than aspirin in this setting
[0.71 vs 0.49%].6
Finally, do we prescribe aspirin for primary
prevention? There are only 4 clinical trials on selected
patients: The US Physician Study, UK Doctors Study
and Thrombosis Prevention Trial all concerned male
subjects, and the Hypertensive Optimal Treatment trial
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History of GIB
due to aspirin

No history of
GIB

1.

Low dose ASA.
No prophylaxis

2.

High risk factors for GIB:
add PPI or use clopidogrel

H. Pylori
Screen
-

+
Treat and resume
aspirin
Add PPI

? Add Nitrate
? Clopidogrel

GIB = Gastrointestinal bleeding
PPI = Proton pump inhibitor
Figure. Prevention of aspirin related gastrointestinal bleeding.

only concerned hypertensive subjects.16 A recent benefit:
risk ratio analysis16 suggests that because of the risk of
cerebral and extracerebral bleeding, aspirin prophylaxis
is only justified when the coronary risk exceeds 0.8%/
year. At a risk of 1%/year, it would be necessary to treat
67 patients over 5 years to prevent a myocardial
infarction, and 182 to prevent a myocardial infarction
without important bleeding. It is here where the "good"
has to be carefully balanced against the "bad" before a
physician should recommend primary aspirin
prophylaxis.
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